TheraRadar
Company Portfolios →

Alnylam Pharmaceuticals

16 active trials across 9 therapeutic areas

16
Active Trials
8
Phase 1
5
Phase 2
6
Phase 3
9
Therapeutic Areas

Immunology

7 active / 19 total
Rheumatoid Arthritis
5 active 4 Ph3
12 total since 2015
Ankylosing Spondylitis
2 active 1 Ph3
7 total since 2015

CNS

4 active / 5 total
Alzheimer's Disease
2 active
2 total since 2015
Neuropathy
1 active 1 Ph3
2 total since 2015
Huntington's Disease
1 active
1 total since 2015

Metabolic

3 active / 5 total
Type 2 Diabetes
2 active
3 total since 2015
Obesity
1 active
1 total since 2015
NASH/NAFLD
0 active
1 total since 2015

Cardiovascular

1 active / 13 total
Hypertension
1 active 1 Ph3
6 total since 2015
Myocardial Infarction
0 active
7 total since 2015

Oncology

1 active / 1 total
Hepatocellular Carcinoma
1 active
1 total since 2015

Urology

0 active / 3 total
Erectile Dysfunction
0 active
3 total since 2015

Musculoskeletal

0 active / 1 total
Gout
0 active
1 total since 2015

Rare Disease

0 active / 1 total
Spinal Muscular Atrophy
0 active
1 total since 2015

Infectious Disease

0 active / 1 total
Hepatitis B
0 active
1 total since 2015

Click an indication to see competitive landscape (all sponsors in that indication).

Data: ClinicalTrials.gov (2015+)